

January 29, 2026

To,  
Listing/ Compliance Department  
**BSE LTD.**  
Pheroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001  
**SCRIP CODE: 543748**

Dear Sir/Madam,

To,  
Listing/ Compliance Department  
**National Stock Exchange of  
India Limited**  
“Exchange Plaza”, Plot No. C/1,  
G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**SYMBOL: AARTIPHARM**

**Sub: Intimation of Board Meeting**  
**Ref: Regulation 29 of SEBI (Listing Obligations and  
Disclosure Requirements) Regulations, 2015**

---

In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations, 2015”), it is hereby intimated that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, February 09, 2026 to inter-alia, consider & approve the following:

1. Unaudited Financial Results of the Company for the quarter ended December 31, 2025 after these results are reviewed by the Audit Committee of the Board.
2. Declaration of Interim Dividend, if any, on the equity share capital of the Company for the Financial Year 2025-26.

Further, in terms of Code for Prevention of Insider Trading in the Securities of the Company, the Trading Window for transactions in the securities of the Company which was closed from January 01, 2026, shall remain closed until February 11, 2026 for the purpose of announcement of aforesaid results.

Please take the same on your records.

Thanking you,

Yours faithfully,  
**For AARTI PHARMALABS LIMITED**

**JEEVAN MONDKAR**  
**COMPANY SECRETARY AND LEGAL HEAD**  
**ICSI M. NO. 22565**